181 related articles for article (PubMed ID: 14534730)
1. Evaluation of MUC1 splice variants as prognostic markers in patients with ductal carcinoma in situ of the breast.
Schmid BC; Rudas M; Fabjani G; Speiser P; Kaserer K; Leodolter S; Zeillinger R
Oncol Rep; 2003; 10(6):1981-5. PubMed ID: 14534730
[TBL] [Abstract][Full Text] [Related]
2. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
[TBL] [Abstract][Full Text] [Related]
3. Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis.
Schuetz CS; Bonin M; Clare SE; Nieselt K; Sotlar K; Walter M; Fehm T; Solomayer E; Riess O; Wallwiener D; Kurek R; Neubauer HJ
Cancer Res; 2006 May; 66(10):5278-86. PubMed ID: 16707453
[TBL] [Abstract][Full Text] [Related]
4. Novel MUC1 splice variants are expressed in cervical carcinoma.
Obermair A; Schmid BC; Stimpfl M; Fasching B; Preyer O; Leodolter S; Crandon AJ; Zeillinger R
Gynecol Oncol; 2001 Nov; 83(2):343-7. PubMed ID: 11606095
[TBL] [Abstract][Full Text] [Related]
5. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
6. Changes in tenascin-C isoform expression in invasive and preinvasive breast disease.
Adams M; Jones JL; Walker RA; Pringle JH; Bell SC
Cancer Res; 2002 Jun; 62(11):3289-97. PubMed ID: 12036947
[TBL] [Abstract][Full Text] [Related]
7. MUC1 oncogene amplification correlates with protein overexpression in invasive breast carcinoma cells.
Lacunza E; Baudis M; Colussi AG; Segal-Eiras A; Croce MV; Abba MC
Cancer Genet Cytogenet; 2010 Sep; 201(2):102-10. PubMed ID: 20682394
[TBL] [Abstract][Full Text] [Related]
8. Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer.
Wang L; Hoque A; Luo RZ; Yuan J; Lu Z; Nishimoto A; Liu J; Sahin AA; Lippman SM; Bast RC; Yu Y
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3660-6. PubMed ID: 14506155
[TBL] [Abstract][Full Text] [Related]
9. MUC1 splice variants in human ocular surface tissues: possible differences between dry eye patients and normal controls.
Imbert Y; Darling DS; Jumblatt MM; Foulks GN; Couzin EG; Steele PS; Young WW
Exp Eye Res; 2006 Sep; 83(3):493-501. PubMed ID: 16631167
[TBL] [Abstract][Full Text] [Related]
10. Lack of polymorphism in MUC1 tandem repeats in cancer cells is related to breast cancer progression in Japanese women.
Kawaguchi T; Takazawa H; Imai S; Morimoto J; Watanabe T
Breast Cancer Res Treat; 2005 Aug; 92(3):223-30. PubMed ID: 16155793
[TBL] [Abstract][Full Text] [Related]
11. Inhibin/activin subunits (inhibin-alpha, -betaA and -betaB) are differentially expressed in human breast cancer and their metastasis.
Mylonas I; Jeschke U; Shabani N; Kuhn C; Friese K; Gerber B
Oncol Rep; 2005 Jan; 13(1):81-8. PubMed ID: 15583806
[TBL] [Abstract][Full Text] [Related]
12. S100A7 (psoriasin) expression is associated with aggressive features and alteration of Jab1 in ductal carcinoma in situ of the breast.
Emberley ED; Alowami S; Snell L; Murphy LC; Watson PH
Breast Cancer Res; 2004; 6(4):R308-15. PubMed ID: 15217497
[TBL] [Abstract][Full Text] [Related]
13. LEA.135 expression: identifies low-risk patients with breast ductal carcinoma in situ.
Baltayan A; Naritoku WY; Chaiwun B; Tsao-Wei DD; Groshen S; Hern RA; Gusterson BA; Taylor CR; Imam SA
Anticancer Res; 2002; 22(5):2933-7. PubMed ID: 12530020
[TBL] [Abstract][Full Text] [Related]
14. RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression.
Subramaniam MM; Chan JY; Soong R; Ito K; Ito Y; Yeoh KG; Salto-Tellez M; Putti TC
Breast Cancer Res Treat; 2009 Jan; 113(1):113-21. PubMed ID: 18256927
[TBL] [Abstract][Full Text] [Related]
15. Genetic pathways in the evolution of breast ductal carcinoma in situ.
Farabegoli F; Champeme MH; Bieche I; Santini D; Ceccarelli C; Derenzini M; Lidereau R
J Pathol; 2002 Mar; 196(3):280-6. PubMed ID: 11857490
[TBL] [Abstract][Full Text] [Related]
16. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
[TBL] [Abstract][Full Text] [Related]
17. Genomic differences between pure ductal carcinoma in situ of the breast and that associated with invasive disease: a calibrated aCGH study.
Iakovlev VV; Arneson NC; Wong V; Wang C; Leung S; Iakovleva G; Warren K; Pintilie M; Done SJ
Clin Cancer Res; 2008 Jul; 14(14):4446-54. PubMed ID: 18628458
[TBL] [Abstract][Full Text] [Related]
18. Patterns of chromosomal alterations in breast ductal carcinoma in situ.
Hwang ES; DeVries S; Chew KL; Moore DH; Kerlikowske K; Thor A; Ljung BM; Waldman FM
Clin Cancer Res; 2004 Aug; 10(15):5160-7. PubMed ID: 15297420
[TBL] [Abstract][Full Text] [Related]
19. The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma.
van der Vegt B; de Roos MA; Peterse JL; Patriarca C; Hilkens J; de Bock GH; Wesseling J
Histopathology; 2007 Sep; 51(3):322-35. PubMed ID: 17645748
[TBL] [Abstract][Full Text] [Related]
20. Comparative genomic hybridization of ductal carcinoma in situ of the breast-evidence of multiple genetic pathways.
Buerger H; Otterbach F; Simon R; Poremba C; Diallo R; Decker T; Riethdorf L; Brinkschmidt C; Dockhorn-Dworniczak B; Boecker W
J Pathol; 1999 Mar; 187(4):396-402. PubMed ID: 10398097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
